Brokerages Set uniQure (NASDAQ:QURE) PT at $32.00

Shares of uniQure (NASDAQ:QURE) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $32.00.

Several analysts recently commented on the company. HC Wainwright dropped their price target on uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 target price on shares of uniQure in a research report on Tuesday, January 16th. The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Mizuho cut their price objective on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Monday, March 4th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research report on Friday, March 1st.

uniQure Stock Up 0.6 %

QURE opened at $4.72 on Friday. The company has a fifty day moving average of $5.07 and a two-hundred day moving average of $5.90. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. uniQure has a fifty-two week low of $4.25 and a fifty-two week high of $22.48. The stock has a market capitalization of $225.80 million, a price-to-earnings ratio of -0.73 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.01. The company had revenue of $6.69 million during the quarter, compared to analyst estimates of $3.20 million. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. On average, research analysts expect that uniQure will post -4.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total transaction of $177,190.40. Following the sale, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Christian Klemt sold 15,906 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.38, for a total value of $101,480.28. Following the completion of the transaction, the chief financial officer now owns 116,948 shares in the company, valued at $746,128.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 27,904 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total transaction of $177,190.40. Following the completion of the sale, the chief executive officer now directly owns 440,839 shares in the company, valued at $2,799,327.65. The disclosure for this sale can be found here. Insiders have sold a total of 53,265 shares of company stock worth $339,845 in the last ninety days. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently modified their holdings of QURE. BNP Paribas Financial Markets boosted its position in shares of uniQure by 4.3% during the 1st quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after acquiring an additional 30,054 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in uniQure by 74.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock worth $818,000 after purchasing an additional 66,958 shares in the last quarter. Privium Fund Management B.V. raised its holdings in uniQure by 30.3% during the first quarter. Privium Fund Management B.V. now owns 578,915 shares of the biotechnology company’s stock worth $3,010,000 after purchasing an additional 134,767 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 58.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after buying an additional 3,664 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of uniQure in the 4th quarter valued at $195,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.